Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Probucol trial for secondary prevention of atherosclerotic events in patients with coronary heart disease (PROSPECTIVE)
[PubMed: 37364590] Lau DCW, Erichsen L, Francisco AM, et al
These findings are virtually identical to the results of the STEP 1 trial for the 2.4 mg injectable semaglutide, which reported a 14.9%-16% weight reduction over a similar period
The side effect profiles are similar, with gastrointestinal symptoms being most common for both
#ObesityManagement #WeightLoss #Health #EvidenceBased #BehavioralTherapy #Nutrition #Pharmacotherapy #BariatricSurgery #ChronicDisease #PublicHealth #JAMA #MedicalReview #BMI #BodyMassIndex #Adiposity #Comorbidities #MetabolicHealth #Diabetes #Hypertension #MedicalResearch #GlobalHealth #Mauritius #WeightLossJourney #Wellness #TreatmentOptions #ClinicalGuidelines #ObesityAwareness To view or add a comment, sign in The whole environment is one-size-fits-all, and in no way are people one-size-fits-all
